Russia’s sovereign wealth fund Russian Direct Investment Fund (RDIF) and VABIOTECH, one of Vietnam’s leading pharmaceutical companies, announced the production of a test batch of the Russian Sputnik V COVID-19 vaccine.
|The first batch of the Russian Sputnik V COVID-19 vaccine was produced in Vietnam |
Kirill Dmitriev, CEO of RDIF, commented: “The RDIF and VABIOTECH are actively cooperating in the technology transfer process to provide easier access to Sputnik V for the population of Vietnam. As the pandemic is far from over and new, more dangerous variants of coronavirus are being detected in various regions of the world, RDIF is increasing capacities for production of Sputnik V to speed up vaccination with one of the best vaccines in the world.”
The first validation samples taken from the produced batch will be shipped to the Gamaleya Center for the quality control. Sputnik V was granted the approval by Vietnam's Ministry of Health on March 23, 2021.
On the same note, Dat Tuan Do, president of VABIOTECH, said that, “It is a great pleasure for us to work with the RDIF to bring Sputnik V to Vietnam to fight the pandemic. We hope the cooperation between the RDIF and VABIOTECH will help provide quality and affordable COVID-19 vaccine to Vietnam and other Southeast Asian countries.”
To date, Sputnik V has been registered in 68 countries with a total population of over 3.7 billion people, which is nearly half of the global population.
Sputnik V is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.